KR102814241B1 - 전안방내 약물 전달 데포 - Google Patents

전안방내 약물 전달 데포 Download PDF

Info

Publication number
KR102814241B1
KR102814241B1 KR1020247011510A KR20247011510A KR102814241B1 KR 102814241 B1 KR102814241 B1 KR 102814241B1 KR 1020247011510 A KR1020247011510 A KR 1020247011510A KR 20247011510 A KR20247011510 A KR 20247011510A KR 102814241 B1 KR102814241 B1 KR 102814241B1
Authority
KR
South Korea
Prior art keywords
hydrogel
depot
depot composition
xerogel
travoprost
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020247011510A
Other languages
English (en)
Korean (ko)
Other versions
KR20240051303A (ko
Inventor
아마프리트 에스. 소니
아서 드리스콜
찰스 디. 블리자드
안키타 다르샨 데사이
피터 자렛
Original Assignee
인셉트, 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 인셉트, 엘엘씨 filed Critical 인셉트, 엘엘씨
Publication of KR20240051303A publication Critical patent/KR20240051303A/ko
Application granted granted Critical
Publication of KR102814241B1 publication Critical patent/KR102814241B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
    • A61F9/0017—Introducing ophthalmic products into the ocular cavity or retaining products therein implantable in, or in contact with, the eye, e.g. ocular inserts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/007—Methods or devices for eye surgery
    • A61F9/00781—Apparatus for modifying intraocular pressure, e.g. for glaucoma treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0092—Hollow drug-filled fibres, tubes of the core-shell type, coated fibres, coated rods, microtubules or nanotubes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Nanotechnology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020247011510A 2016-09-23 2017-09-25 전안방내 약물 전달 데포 Active KR102814241B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662398985P 2016-09-23 2016-09-23
US62/398,985 2016-09-23
PCT/US2017/053271 WO2018058048A1 (en) 2016-09-23 2017-09-25 Intracameral drug delivery depots
KR1020237011914A KR20230053707A (ko) 2016-09-23 2017-09-25 전안방내 약물 전달 데포

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020237011914A Division KR20230053707A (ko) 2016-09-23 2017-09-25 전안방내 약물 전달 데포

Publications (2)

Publication Number Publication Date
KR20240051303A KR20240051303A (ko) 2024-04-19
KR102814241B1 true KR102814241B1 (ko) 2025-05-29

Family

ID=60022215

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020197011614A Active KR102520771B1 (ko) 2016-09-23 2017-09-25 전안방내 약물 전달 데포
KR1020237011914A Ceased KR20230053707A (ko) 2016-09-23 2017-09-25 전안방내 약물 전달 데포
KR1020247011510A Active KR102814241B1 (ko) 2016-09-23 2017-09-25 전안방내 약물 전달 데포

Family Applications Before (2)

Application Number Title Priority Date Filing Date
KR1020197011614A Active KR102520771B1 (ko) 2016-09-23 2017-09-25 전안방내 약물 전달 데포
KR1020237011914A Ceased KR20230053707A (ko) 2016-09-23 2017-09-25 전안방내 약물 전달 데포

Country Status (10)

Country Link
US (3) US12171869B2 (enExample)
EP (2) EP3515406B1 (enExample)
JP (2) JP7430529B2 (enExample)
KR (3) KR102520771B1 (enExample)
CN (1) CN109982683A (enExample)
AU (1) AU2017331444B2 (enExample)
DK (1) DK3515406T3 (enExample)
ES (1) ES2989941T3 (enExample)
IL (1) IL265421B2 (enExample)
WO (1) WO2018058048A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11458041B2 (en) 2015-10-08 2022-10-04 Ocular Therapeutix, Inc. Punctal plug and bioadhesives
KR102520771B1 (ko) * 2016-09-23 2023-04-12 인셉트, 엘엘씨 전안방내 약물 전달 데포
WO2020181393A1 (en) * 2019-03-13 2020-09-17 Susmita Bose Enzyme-degradable hydrogel for delivery of a payload
CN113939274A (zh) * 2019-04-25 2022-01-14 视觉治疗股份有限公司 用于降低眼内压的水凝胶植入物
WO2020219890A1 (en) * 2019-04-25 2020-10-29 Ocular Therapeutix, Inc. Ocular hydrogel tyrosine kinase inhibitor implants
EP3958839A1 (en) * 2019-04-25 2022-03-02 Ocular Therapeutix, Inc. Intracanalicular hydrogel inserts for the delivery of anesthetics
DK3861985T3 (da) * 2020-02-06 2023-07-24 Ocular Therapeutix Inc Sammensætninger og fremgangsmåder til behandling af øjensygdomme
DK3884929T3 (da) * 2020-03-25 2023-09-25 Ocular Therapeutix Inc Øjenimplantat indeholdende en tyrosinkinase-inhibitor
CN115768385A (zh) 2020-04-27 2023-03-07 视觉治疗股份有限公司 治疗过敏性结膜炎的方法
JP2023534952A (ja) * 2020-07-16 2023-08-15 オキュラ セラピューティクス，インコーポレイテッド グルココルチコイドを含む眼内挿入物
BR112023004378A2 (pt) * 2020-09-24 2023-04-04 Ocular Therapeutix Inc Insertos intracanaliculares biodegradáveis de liberação sustentada que compreendem um hidrogel e uma ciclosporina
WO2022066891A1 (en) * 2020-09-24 2022-03-31 Ocular Therapeutix, Inc. Sustained release biodegradable intracanalicular inserts comprising a hydrogel and an active agent
US20220378612A1 (en) * 2021-05-28 2022-12-01 Sight Sciences, Inc. Intraocular devices, systems, and methods
CN114748436B (zh) * 2022-05-30 2023-05-16 迪沙药业集团有限公司 一种硝苯地平组合物及其制备方法
JP2025526731A (ja) * 2022-08-12 2025-08-15 オキュラ セラピューティクス，インコーポレイテッド 持続的薬物送達のためのオルガノゲル、その調製及び使用の方法
CN115337453A (zh) * 2022-08-15 2022-11-15 珠海肤原生物科技有限公司 一种载有2-氧杂环庚烷酮的均聚物微球的医用无菌胶原蛋白产品的制备
WO2024191453A1 (en) * 2023-03-10 2024-09-19 Clearstream Technologies Limited Radiation spacer hydrogels, methods of forming, and methods of use
WO2024215649A1 (en) 2023-04-11 2024-10-17 Ocular Therapeutix, Inc. Ocular implant comprising axitinib polymorph iv

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100209478A1 (en) 2009-02-12 2010-08-19 Sawhney Amarpreet S Drug delivery through hydrogel plugs
WO2010111449A1 (en) 2009-03-25 2010-09-30 Allergan, Inc. Intraocular sustained release drug delivery systems and methods for treating ocular conditions
WO2016094646A1 (en) 2014-12-10 2016-06-16 Incept, Llc Hydrogel drug delivery implants

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3640741A (en) 1970-02-24 1972-02-08 Hollister Inc Composition containing gel
US3865108A (en) 1971-05-17 1975-02-11 Ortho Pharma Corp Expandable drug delivery device
US4002173A (en) 1974-07-23 1977-01-11 International Paper Company Diester crosslinked polyglucan hydrogels and reticulated sponges thereof
DE2437629C3 (de) 1974-08-05 1978-09-21 Basf Ag, 6700 Ludwigshafen Verfahren zur Herstellung von unlöslichen in Wasser nur wenig quellbaren Polymerisaten von N-Vinyllactamen
US4014335A (en) 1975-04-21 1977-03-29 Alza Corporation Ocular drug delivery device
US4207893A (en) 1977-08-29 1980-06-17 Alza Corporation Device using hydrophilic polymer for delivering drug to biological environment
US5160745A (en) 1986-05-16 1992-11-03 The University Of Kentucky Research Foundation Biodegradable microspheres as a carrier for macromolecules
US4741872A (en) 1986-05-16 1988-05-03 The University Of Kentucky Research Foundation Preparation of biodegradable microspheres useful as carriers for macromolecules
IL82834A (en) 1987-06-09 1990-11-05 Yissum Res Dev Co Biodegradable polymeric materials based on polyether glycols,processes for the preparation thereof and surgical artiicles made therefrom
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5304595A (en) 1988-11-21 1994-04-19 Collagen Corporation Collagen-polymer conjugates
US5162430A (en) 1988-11-21 1992-11-10 Collagen Corporation Collagen-polymer conjugates
IL90193A (en) 1989-05-04 1993-02-21 Biomedical Polymers Int Polurethane-based polymeric materials and biomedical articles and pharmaceutical compositions utilizing the same
FR2657018A1 (fr) 1990-01-12 1991-07-19 Merck Sharp & Dohme Composition ophtalmique fluide a base de microparticules lipidiques contenant au moins un principe actif et son procede de preparation.
US5410016A (en) 1990-10-15 1995-04-25 Board Of Regents, The University Of Texas System Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers
US6177401B1 (en) 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
US6371975B2 (en) 1998-11-06 2002-04-16 Neomend, Inc. Compositions, systems, and methods for creating in situ, chemically cross-linked, mechanical barriers
EP1027016A4 (en) 1997-10-27 2006-03-08 Univ California METHODS AND PHARMACEUTICAL COMPOSITIONS FOR REFERRING RETINAL RIPPLE
US6632457B1 (en) 1998-08-14 2003-10-14 Incept Llc Composite hydrogel drug delivery systems
US6958212B1 (en) 1999-02-01 2005-10-25 Eidgenossische Technische Hochschule Zurich Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds
US7141581B2 (en) 1999-07-02 2006-11-28 Agouron Pharmaceuticals, Inc. Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
TWI262914B (en) 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
US20050049578A1 (en) 2000-04-14 2005-03-03 Hosheng Tu Implantable ocular pump to reduce intraocular pressure
ATE306951T1 (de) 2000-11-29 2005-11-15 Allergan Inc Verhinderung von transplantatabstossung im auge
MXPA03007665A (es) 2001-02-26 2004-03-16 Univ Duke Polimeros dendriticos novedosos y sus usos biomedicos.
US6913765B2 (en) 2001-03-21 2005-07-05 Scimed Life Systems, Inc. Controlling resorption of bioresorbable medical implant material
US20040131582A1 (en) 2002-02-26 2004-07-08 Grinstaff Mark W. Novel dendritic polymers and their biomedical uses
US20040024345A1 (en) 2002-04-19 2004-02-05 Morteza Gharib Glaucoma implant with valveless flow bias
US7351430B2 (en) 2002-11-06 2008-04-01 Uluru Inc. Shape-retentive hydrogel particle aggregates and their uses
US20040137059A1 (en) 2003-01-09 2004-07-15 Thierry Nivaggioli Biodegradable ocular implant
US7129210B2 (en) 2003-07-23 2006-10-31 Covalent Medical, Inc. Tissue adhesive sealant
US8673341B2 (en) 2004-04-30 2014-03-18 Allergan, Inc. Intraocular pressure reduction with intracameral bimatoprost implants
US20050244458A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular neuropathies
WO2006031358A2 (en) 2004-08-13 2006-03-23 Hyperbranch Medical Technology, Inc. Dendritic polymers, crosslinked gels, and their uses as ophthalmic sealants and lenses
WO2006031388A2 (en) 2004-08-20 2006-03-23 Hyperbranch Medical Technology, Inc. Dentritic polymers, crosslinked gels, and their uses in orthopedic applications
US20080038316A1 (en) 2004-10-01 2008-02-14 Wong Vernon G Conveniently implantable sustained release drug compositions
WO2007001926A2 (en) 2005-06-24 2007-01-04 Hyperbranch Medical Technology, Inc. Low-swelling hydrogel sealants for wound repair
WO2007005249A2 (en) 2005-06-29 2007-01-11 Hyperbranch Medical Technology, Inc. Nanoparticles and dendritic-polymer-based hydrogels comprising them
US9173773B2 (en) * 2006-06-21 2015-11-03 Johnson & Johnson Vision Care, Inc. Punctal plugs for the delivery of active agents
US9125807B2 (en) 2007-07-09 2015-09-08 Incept Llc Adhesive hydrogels for ophthalmic drug delivery
US8895508B2 (en) 2009-07-24 2014-11-25 Yasuhiki Tabata Methods for corneal endothelial proliferation using bFGF sustained-release gelatin hydrogel particles
US8176360B2 (en) 2009-08-11 2012-05-08 Texas Memory Systems, Inc. Method and apparatus for addressing actual or predicted failures in a FLASH-based storage system
EP3960215B1 (en) 2009-12-15 2024-10-16 Incept, LLC Implants and biodegradable fiducial markers
ES2561083T3 (es) 2010-01-22 2016-02-24 Allergan, Inc. Implantes intracamerales de agentes terapéuticos de liberación sostenida
WO2011106702A2 (en) 2010-02-25 2011-09-01 The Johns Hopkins University Sustained delivery of therapeutic agents to an eye compartment
BR112012025581A2 (pt) 2010-04-06 2019-09-24 Allergan Inc implantes de reservatório de liberação sustentada para distribuição de fármaco intracameral
US8961501B2 (en) 2010-09-17 2015-02-24 Incept, Llc Method for applying flowable hydrogels to a cornea
US10226417B2 (en) * 2011-09-16 2019-03-12 Peter Jarrett Drug delivery systems and applications
AU2012347926B2 (en) 2011-12-05 2018-03-15 Incept, Llc Medical organogel processes and compositions
US9283231B2 (en) 2013-01-31 2016-03-15 Icon Bioscience, Inc. Sustained release formulations for the treatment of intraocular pressure of glaucoma
ES2930433T3 (es) * 2013-03-05 2022-12-12 Univ Pittsburgh Commonwealth Sys Higher Education Hidrogel termosensible que contiene micropartículas de polímero para la administración ocular no invasiva de fármaco
US9289413B2 (en) 2013-03-15 2016-03-22 Allergan, Inc. Prostamide-containing intraocular implant
CA2908645A1 (en) 2013-04-01 2014-10-09 Allergan, Inc. Microsphere drug delivery system for sustained intraocular release
CN106132397A (zh) 2013-12-06 2016-11-16 恩维希亚治疗股份有限公司 用于治疗眼部疾病的前房内植入物
AU2016361579B2 (en) 2015-11-25 2022-08-04 Incept, Llc Shape changing drug delivery devices and methods
KR102520771B1 (ko) 2016-09-23 2023-04-12 인셉트, 엘엘씨 전안방내 약물 전달 데포

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100209478A1 (en) 2009-02-12 2010-08-19 Sawhney Amarpreet S Drug delivery through hydrogel plugs
WO2010111449A1 (en) 2009-03-25 2010-09-30 Allergan, Inc. Intraocular sustained release drug delivery systems and methods for treating ocular conditions
WO2016094646A1 (en) 2014-12-10 2016-06-16 Incept, Llc Hydrogel drug delivery implants

Also Published As

Publication number Publication date
DK3515406T3 (da) 2024-10-14
ES2989941T3 (es) 2024-11-28
JP2019529455A (ja) 2019-10-17
EP3515406A1 (en) 2019-07-31
IL265421B1 (en) 2023-12-01
US20180085307A1 (en) 2018-03-29
KR20190057353A (ko) 2019-05-28
CA3038075A1 (en) 2018-03-29
JP2022091998A (ja) 2022-06-21
EP3515406B1 (en) 2024-07-24
IL265421B2 (en) 2024-04-01
WO2018058048A1 (en) 2018-03-29
US20220401356A1 (en) 2022-12-22
KR20240051303A (ko) 2024-04-19
US12171869B2 (en) 2024-12-24
KR102520771B1 (ko) 2023-04-12
KR20230053707A (ko) 2023-04-21
AU2017331444A1 (en) 2019-04-18
US20250144012A1 (en) 2025-05-08
EP4197527A1 (en) 2023-06-21
BR112019005594A2 (pt) 2019-08-13
JP7486539B2 (ja) 2024-05-17
CN109982683A (zh) 2019-07-05
AU2017331444B2 (en) 2023-08-17
IL265421A (en) 2019-05-30
JP7430529B2 (ja) 2024-02-13

Similar Documents

Publication Publication Date Title
JP7486539B2 (ja) 前房内薬物送達デポ
JP7599732B2 (ja) ハイドロゲルからの薬物送達
JP7092502B2 (ja) ハイドロゲル薬物送達インプラント
KR102039468B1 (ko) 의료용 유기젤 방법 및 조성물
KR20180086468A (ko) 형상 변형 약물 전달 장치 및 방법
CA3038075C (en) Intracameral drug delivery depots
BR122024018825A2 (pt) Composição de depósito e uso da mesma para tratamento de uma condição ocular
BR112019005594B1 (pt) Composição de depósito intracameral e uso da mesma para tratamento de uma condição ocular
HK1261346A1 (en) Shape changing drug delivery devices and methods
HK1203367B (zh) 醫用有機凝膠方法和組合物

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20240405

Application number text: 1020237011914

Filing date: 20230406

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20240503

Comment text: Request for Examination of Application

PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240701

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20250311

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20250526

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20250527

End annual number: 3

Start annual number: 1

PG1601 Publication of registration